- Synthesis and properties of 1,3,4-oxadiazole-containing bismaleimides with asymmetric structure and the copolymerized systems thereof with 4,4′-bismaleimidodiphenylmethane
-
Two novel bismaleimide monomers containing 1,3,4-oxadiazole and asymmetric structure, i.e., 2-[4-(4-maleimidophenoxy)phenyl]-5-(4-maleimidophenyl)-1,3,4- oxadiazole (p-Mioxd) and 2-[3-(4-maleimidophenoxy)phenyl]-5-(4-maleimidophenyl)- 1,3,4-oxadiazole (m-Mioxd), were designed and synthesized. The chemical structures of the monomers were confirmed using Fourier transform infrared spectroscopy (FTIR), 1H NMR and 13C NMR spectroscopy and elemental analysis. The thermal properties of the monomers were investigated by differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). The results indicate that the incorporation of the 1,3,4-oxadiazole and asymmetric structure could improve the solubility and processability of the BMI monomers and the thermal stability of the resins. Composites composed of glass cloth and 4,4′-bismaleimidodiphenylmethane (BMDM), which were modified with 2.5, 5 and 10 wt% p-Mioxd and m-Mioxd, respectively, were also prepared. The TGA and DMA results demonstrate that the resulting composites have excellent thermal stability with high residual weight percentage at 700 °C (>45%) and Tg (>450 °C).
- Xia, Lianlian,Zhai, Xuejiao,Xiong, Xuhai,Chen, Ping
-
-
Read Online
- Synthesis and biological evaluation of novel thiadiazole amides as potent Cdc25B and PTP1B inhibitors
-
A series of novel thiadiazole amide derivatives have been synthesized and evaluated for inhibitory activities against Cdc25B and PTP1B. Most of them showed inhibitory activities against Cdc25B (IC50 = 1.18-8.01 μg/mL) and PTP1B (IC50 = 0.85-8.75 μg/mL), respectively. Moreover, compounds 5b and 4l were most potent with IC50 values of 1.18 and 0.85 μg/mL for Cdc25B and PTP1B, respectively, compared with reference drugs Na3VO4 (IC50 = 0.93 μg/mL) and oleanolic acid (IC50 = 0.85 μg/mL). The results of selectivity experiments showed that the target compounds were selective inhibitors against PTP1B and Cdc25B. Enzyme kinetic experiments demonstrated that compound 5k was a specific inhibitor with the typical characteristics of a mixed inhibitor.
- Li, Yingjun,Yu, Yang,Jin, Kun,Gao, Lixin,Luo, Tongchuan,Sheng, Li,Shao, Xin,Li, Jia
-
-
Read Online
- Synthesis and structure–activity relationship of N-(piperidin-4-yl)benzamide derivatives as activators of hypoxia-inducible factor 1 pathways
-
Guided by bioisosterism and pharmacokinetic parameters, we designed and synthesized a series of novel benzamide derivatives. Preliminary in vitro studies indicated that compounds 10b and 10j show significant inhibitory bioactivity in HepG2 cells (IC50 values of 0.12 and 0.13?μM, respectively). Compounds 10b and 10j induced the expression of HIF-1α protein and downstream target gene p21, and upregulated the expression of cleaved caspase-3 to promote tumor cells apoptosis.
- Huang, Zhi-Ning,Liang, Han,Qiao, Hong,Wang, Bao-Rui,Qu, Ning,Li, Hua,Zhou, Run-Run,Wang, Li-Juan,Li, Shan-Hua,Li, Fu-Nan
-
p. 1149 - 1161
(2018/07/21)
-
- Ultrasound synthesis of diaryl ethers
-
2,2-Bis[4-(4-nitroaryl)phenyl]hexafluoropropanes appropriate for the synthesis of monomers were prepared by the reaction of 2,2-bis[4-hydroxyphenyl)hexafluoropropane with 1-chloro-4-nitrobenzenes under ultrasonic activation.
- Begunov,Valyaeva,Belyaev,Dobretsova
-
p. 1971 - 1974
(2016/05/11)
-
- Synthesis of diaryl ethers, diaryl sulfides, heteroaryl ethers and heteroaryl sulfides under microwave dielectric heating
-
This paper describes the synthesis of diaryl ethers and sulfides by utilizing microwave heating methodology. The methodology is shown to be rapid and efficient for the coupling of phenols or thiophenol with electron-deficient aryl halides through a SNAr reaction. The scope of the protocol can be expanded to six-membered heterocycles bearing a hydroxyl group as well as to the reaction of 2-pyrimidinethiol with mildly activated aryl halides, providing heteroaryl ethers and sulfides, respectively. The advantages of the present method include the wide substrate scope, the obviation of metal catalysts, ease of product isolation, and high purity of products. Georg Thieme Verlag Stuttgart.
- Li, Feng,Meng, Qingqing,Chen, Huansheng,Li, Zhiming,Wang, Quanrui,Tao, Fenggang
-
p. 1305 - 1313
(2007/10/03)
-
- Protease inhibitors
-
The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.
- -
-
-